Introduction
============

Colorectal cancer (CRC) is the fourth most common cancer site in the US and the fourth most frequent cause of cancer-related death. In 2010, the estimated number of CRC cases was 142,570, with 51,370 cancer-related deaths.[@b1-ott-5-199] Given that the prognosis of these patients is poor, improvement of treatment remains a priority. Although surgery and chemotherapy are the mainstay of treatment for CRC, their efficacy in patients with metastatic CRC remains unsatisfactory. Based on mechanisms involved in oncogenesis, treatment of metastatic CRC includes both conventional drugs, such as 5-fluorouracil (5-FU) or capecitabine, irinotecan (CPT-11), oxaliplatin (L-OHP), and new targeted agents, such as bevacizumab, cetuximab, and panitumumab. Novel therapeutic approaches have focused on the role of angiogenesis-targeting inhibitors. Angiogenesis is a crucial mechanism for both primary tumor growth and development of metastases.[@b2-ott-5-199],[@b3-ott-5-199] Tumor angiogenesis is associated with invasiveness and the metastatic potential of various cancers because of abnormalities in blood vessels supplying tumors' structure and function. Vascular endothelial growth factor (VEGF), the most potent and specific angiogenic factor, regulates normal and pathologic angiogenesis. Increased expression of VEGF has been correlated with risk of metastasis, recurrence, and poor prognosis in many cancers, including CRC.[@b4-ott-5-199]--[@b6-ott-5-199] Consequently, a recombinant humanized monoclonal antibody against VEGF, ie, bevacizumab, has been introduced as an antiangiogenic therapeutic strategy in cancer.[@b3-ott-5-199],[@b7-ott-5-199] It was been found to inhibit the growth of several tumor types in animal models, and was well tolerated in Phase I studies.[@b4-ott-5-199],[@b8-ott-5-199] Phase III clinical trials demonstrated its efficacy in different metastatic cancers.[@b9-ott-5-199],[@b10-ott-5-199] In patients with metastatic CRC, bevacizumab significantly improves both the tumor response rate and progression-free survival when added to 5-FU and folinic acid (FA).[@b3-ott-5-199],[@b11-ott-5-199],[@b12-ott-5-199] Subsequent randomized trials showed that bevacizumab increased overall survival, the median being 20.3 months versus 15.6 months when the drug was combined with 5-FU-FA-CPT-11 (IFL schedule) as initial treatment. [@b3-ott-5-199],[@b13-ott-5-199] Similarly, when added to L-OHP-5-FU-FA (FOLFOX), bevacizumab increased median overall survival (12.9 months versus 10.8 months) following failure on CPT-11-containing regimens,[@b3-ott-5-199],[@b14-ott-5-199] and was able to improve the response rate and progression-free survival when combined with either infusional 5-fluorouracil-bolus folinic acid-irinotecan (FOLFIRI) or FOLFOX in patients with untreated metastatic colorectal cancer.[@b3-ott-5-199],[@b15-ott-5-199] The use of bevacizumab as neoadjuvant treatment is another clinically relevant issue.[@b16-ott-5-199] In such a patient setting, addition of bevacizumab increased the objective response rate, so favoring downstaging of the disease and the switch from nonresectable to resectable CRC liver metastasis, increasing the R0 resection rate, as well as sterilization of micrometastatic disease.

Based on data emerging from Phase II, III, and IV trials involving bevacizumab, we developed this systemic review to describe better the effectiveness and tolerability of bevacizumab in combination with standard chemotherapy in the various treatment lines for patients with metastatic colorectal cancer.

Angiogenesis and vascular endothelial growth factor
===================================================

Angiogenesis is an essential mechanism for both primary tumor growth and metastasis. Indeed, tumors receive sufficient nutrients and oxygen by simple diffusion up to a size of 1--2 mm, but further growth requires a vascular supply. This process involves formation of new blood vessels which infiltrate the tumor mass.[@b17-ott-5-199] In addition, both physiologic and tumoral angiogenesis involve recruitment of circulating endothelial precursor cells from the bone marrow to promote neovascularization.[@b18-ott-5-199],[@b19-ott-5-199] Blood vessels supplying tumors have a number of abnormalities in their structure and function.[@b20-ott-5-199] Secretion of VEGF alters the balance between endothelial cell proliferation and apoptosis, resulting in increased cell division and angiogenesis.[@b21-ott-5-199],[@b22-ott-5-199] Moreover, alterations in the walls of new blood vessels make these susceptible to losses.[@b23-ott-5-199] This mechanism increases interstitial fluid pressure, compromising blood flow to the affected area, and has implications for drug delivery to the tumor.[@b24-ott-5-199] Impaired barrier function also increases extravasation of tumor cells, and thus metastasis, while growth factors produced or released by blood monocytes and macrophages contribute to tumor progression.[@b20-ott-5-199],[@b25-ott-5-199] The VEGF receptor is highly expressed on the endothelial cells of blood vessels supplying tumors and promotes growth of endothelial cells in arteries, veins, and lymphatic vessels.[@b26-ott-5-199] In addition, it stimulates angiogenesis in vivo,[@b27-ott-5-199] favors vascular permeability and capillary leak,[@b28-ott-5-199] and induces expression of molecules that control adhesion of leukocytes in models of inflammation.[@b29-ott-5-199] These effects occur through binding of VEGF to VEGF receptor-2 (also known as Flk-1 or KDR).[@b30-ott-5-199]

Bevacizumab and first-line treatment of metastatic CRC
======================================================

Bevacizumab is a humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor A (VEGF-A). Bevacizumab has been investigated for the treatment of different tumors, including metastatic CRC, showing interesting activity with an acceptable profile in term of toxicity. In metastatic CRC, different bevacizumab-based schedules have been developed in order to evaluate the clinical impact of this novel target agent in patients with metastatic CRC. In fact, bevacizumab was studied in diverse combinations of the two most widely used chemotherapy regimens in first-line treatment of metastatic colorectal cancer, ie, FOLFIRI and FOLFOX, and then with the fluoropyrimidine alone, which has always been the cornerstone drug for the treatment of this disease.

Bevacizumab with fluoropyrimidines plus CPT-11 (IFL, FOLFIRI)
-------------------------------------------------------------

The efficacy and tolerability of bevacizumab in combination with bolus 5-FU-FA-CPT-11 (IFL schedule) versus 5-FU-FA-CPT-11 (IFL) alone as first-line treatment have been investigated in 813 patients with advanced colorectal cancer.[@b13-ott-5-199] Patients were randomized to receive IFL + bevacizumab or IFL + placebo. Significant improvements in overall survival, progression-free survival, and response rate were observed with IFL + bevacizumab. In detail, median overall survival was 20.3 months versus 15.6 months (hazards ratio \[HR\] 0.66; *P* \< 0.001), median progression-free survival was 10.6 months versus 6.2 months (HR 0.54; *P* \< 0.001), while the corresponding response rates were, respectively, 44.8% and 34.8% (*P* = 0.004). Therefore, according to these results, bevacizumab was approved for first-line treatment of metastatic CRC by the US Food And Drug Administration in 2004. However, successive studies failed to confirm the overall survival values previously observed.[@b31-ott-5-199] Indeed, a Phase III study randomized 222 treatment-naïve patients to either IFL + bevacizumab or IFL alone, but no significant difference was found for either overall survival or response rate.[@b32-ott-5-199] However, use of infusional 5-FU-based regimens, such as FOLFIRI, was considered a strategy suitable to achieve better results.[@b31-ott-5-199],[@b33-ott-5-199] One study randomized 117 patients to either FOLFIRI + bevacizumab or IFL + bevacizumab.[@b33-ott-5-199] Although the median progression-free survival and response rates did not differ, the FOLFIRI + bevacizumab regimen achieved significantly longer overall survival ([Table 1](#t1-ott-5-199){ref-type="table"}). The combination of IFL or FOLFIRI + bevacizumab was generally well tolerated, with an increase only in hypertensive events in patients treated with bevacizumab.

Bevacizumab with fluoropyrimidines + oxaliplatin (FOLFOX, Capecitabine + L-OHP \[XELOX\])
-----------------------------------------------------------------------------------------

Results of the N9741 study demonstrated the superiority of FOLFOX4 (infusional 5-FU + L-OHP) over IFL in terms of both progression-free and overall survival.[@b4-ott-5-199],[@b36-ott-5-199] Addition of bevacizumab to L-OHP-based chemotherapy achieved a higher progression-free survival as compared with placebo (median 9.4 months versus 8.0 months; HR 0.83; 97.5% confidence interval \[CI\] 0.72--0.95; *P* = 0.0023), while both overall survival and response rate did not significantly differ. The relatively modest improvements in progression-free survival and overall survival associated with bevacizumab may be explained by the inability to continue treatment until progression in the majority of patients, and has led to the hypothesis that continuing bevacizumab alone until disease progression may be necessary.[@b15-ott-5-199] In the TREE-2 trial,[@b37-ott-5-199] 213 untreated patients with metastatic CRC were randomly assigned to bevacizumab in combination with three different schedules of fluoropyrimidines and oxaliplatin. Bevacizumab improved the response rate, time to progression, and median overall survival for all three regimens ([Table 1](#t1-ott-5-199){ref-type="table"}). Toxicities from the FOLFOX and bevacizumab combination were generally characterized by chemotherapy- related events, such as neurotoxicity, gastrointestinal toxicity, and myelosuppression, rather than events related to bevacizumab.

Bevacizumab with fluoropyrimidines alone (5-FU-FA, capecitabine)
----------------------------------------------------------------

The efficacy of bevacizumab in addition to 5-FU-FA versus 5-FU-FA alone in patients with untreated metastatic CRC has been investigated in two randomized Phase II trials.[@b11-ott-5-199],[@b12-ott-5-199] In the first trial,[@b11-ott-5-199] 104 patients were randomly assigned to receive 5-FU-FA combined with bevacizumab 10 mg/kg, 5-FU-FA combined with bevacizumab 5 mg/kg, or 5-FU-FA alone. Bevacizumab was administered until disease progression. Irrespective of dose, improvement in both time to progression and response rate was observed following use of bevacizumab, while there was no significant improvement in median overall survival. Similarly, in the other trial,[@b12-ott-5-199] 209 patients were randomly assigned to either 5-FU-FA + placebo or 5-FU-FA + bevacizumab. The latter regimen achieved better progression-free survival and response rates, but not for overall survival. In another Phase III study,[@b38-ott-5-199] 407 patients with metastatic CRC received capecitabine, capecitabine + bevacizumab, or capecitabine + bevacizumab + mitomycin. Both combined regimens achieved higher progression-free survival as compared with capecitabine alone ([Table 1](#t1-ott-5-199){ref-type="table"}). Bevacizumab in combination with fluoropyrimidines was moderately tolerated, with bleeding, hypertension, and thrombosis more frequently observed in the bevacizumab arm.

Bevacizumab as second-line therapy
==================================

A randomized Phase III trial[@b14-ott-5-199] was designed to evaluate the efficacy of bevacizumab + FOLFOX4 compared with FOLFOX4 alone as second-line therapy for patients with metastatic CRC. Patients were eligible if they had previously received CPT-11 with fluoropyrimidines for advanced disease. Overall, 829 patients were enrolled, whereby 286 received FOLFOX4 + bevacizumab, 291 patients received FOLFOX4 alone, and 243 patients received bevacizumab alone (this arm was closed early due to inferior efficacy). At a median follow-up of 28 months, patients treated with bevacizumab in combination with FOLFOX4 had a median overall survival of 12.9 months as compared with 10.8 months for those treated with FOLFOX4 alone (HR 0.75; *P* = 0.0011). In addition, the combination of bevacizumab and FOLFOX4 resulted in a statistically significant improvement in progression-free survival compared with chemotherapy alone (7.3 versus 4.7 months; HR 0.61; *P* \< 0.0001). In addition, 22.7% and 8.6% of patients achieved a confirmed response following FOLFOX + bevacizumab as compared with FOLFOX alone, respectively (*P* \< 0.000). Therefore, bevacizumab was approved by the US Food And Drug Administration in 2006 as second-line treatment.[@b39-ott-5-199]

Another study investigated the efficacy of bevacizumab + FOLFIRI in patients with metastatic CRC who failed oxaliplatin- containing regimens without bevacizumab.[@b40-ott-5-199] A total of 115 patients received bevacizumab + FOLFIRI after failure of oxaliplatin and fluoropyrimidines ( FOLFIRI + bevacizumab after L-OHP-5-FU group), and 45 patients received bevacizumab + FOLFOX after failure of CPT-11 and fluoropyrimidines (FOLFOX + bevacizumab after CPT- 11-5-FU group). Median progression-free survival were 8.3 months versus 7.8 months, respectively, median overall survival was 21.6 months and 16.5 months, and the response rate was 25% and 29%. Moreover, other studies showed that bevacizumab + CPT-11 was an active and safe treatment option for patients failing L-OHP-based therapy.[@b41-ott-5-199]--[@b43-ott-5-199] BEVACOLOR was a prospective Phase II trial assessing the efficacy and safety of bevacizumab combined with chemotherapy regimens commonly used in the second-line treatment of metastatic CRC. Overall, 53 patients with metastatic CRC who progressed or relapsed after first-line oxaliplatin-based or CPT-11-based treatment received bevacizumab combined with chemotherapy (FOLFIRI, FOLFOX, or capecitabine + CPT-11 \[XELIRI\]) until disease progression. The disease control rate was 87%, the response rate was 32%, the median progression-free survival was 6.5 months, and median overall survival was 19.3 months. These data confirmed the efficacy of bevacizumab in combination with any regimen of chemotherapy as second-line treatment in patients with metastatic CRC.[@b44-ott-5-199]

The efficacy of bevacizumab in combination with fluoropyrimidines has been evaluated as a third-line treatment in 100 patients who failed CPT-11-based and oxaliplatin-based chemotherapy regimens.[@b45-ott-5-199] The response rate was 4%, median progression-free survival was 3.5 months, and median overall survival was 9 months. According to this study, use of third-line fluoropyrimidines + bevacizumab in chemoresistant patients is an ineffective treatment. However, additional reports presented different results.[@b46-ott-5-199] Two studies evaluated the efficacy and safety of bevacizumab + FOLFIRI or FOLFOX in metastatic CRC after failure with FOLFIRI and FOLFOX, using a retrospective analysis. The data showed that bevacizumab + FOLFIRI or FOLFOX (as third-line or more therapy) has modest activity with a relatively tolerable impact.[@b47-ott-5-199],[@b48-ott-5-199] A summary of the data for bevacizumab-combined chemotherapy as a second-line treatment in patients with metastatic CRC is shown in [Table 2](#t2-ott-5-199){ref-type="table"}.

Bevacizumab and neoadjuvant treatment of liver metastases
=========================================================

Surgical resection offers the chance of long-term survival in patients with CRC and hepatic or pulmonary metastases, with a 25%--35% survival rate at 5 years observed after complete resection.[@b52-ott-5-199] European guidelines recommend use of perioperative chemotherapy administered 3 months before and 3 months after surgery in patients with resectable liver metastases.[@b52-ott-5-199] Use of bevacizumab in combination with chemotherapy improves the outcomes in these patients. However, as shown in [Table 3](#t3-ott-5-199){ref-type="table"}, the majority of data come from retrospective studies. Bevacizumab did not significantly improve the response rate when added to a combination of oxaliplatin and fluoropyrimidine compared with oxaliplatin or fluoropyrimidine alone,[@b15-ott-5-199] and there was no statistically significant difference in resection rates in patients treated with bevacizumab compared with placebo.[@b55-ott-5-199]

A recent prospective study enrolled 46 patients with only liver metastases treated with neoadjuvant chemotherapy according to the XELOX + bevacizumab regimen. The radiologic response rate was 78%, the conversion rate of nonresectable liver metastases was 40%, and the rate of surgery with curative intent was 17.7%, with an R0 of 6.52%.[@b54-ott-5-199] Addition of bevacizumab to oxaliplatin-based chemotherapy significantly reduced the number of residual tumor cells as compared with placebo (23% versus 45%, *P* = 0.02),[@b56-ott-5-199] without increasing the complete response rate (11.3% versus 11.6%, *P* = 0.59). Later, in 2010, an additional retrospective analysis[@b57-ott-5-199] on the same two studies assessed the correlation between bevacizumab and tumor regression grade (TRG), and how TRG was associated with overall survival and disease-free survival. Metastases for 100 patients were analyzed, and the results showed an increase in pathologic responses and a reduction of TRG in patients who received neoadjuvant treatment with bevacizumab (*P* = 0.008). In that study, TRG was divided as follows: TRG1--TRG2, greater (major) histologic response; TRG3, partial histologic response; TRG4-- TRG5, no pathologic (histologic) response. In the group of patients treated with bevacizumab, 34% obtained no histologic response versus 66% in the group treated with chemotherapy alone; 38% of patients treated with bevacizumab obtained a major histologic response versus 10% in the group treated with chemotherapy alone (*P* \< 0.001). The same percentage of partial histologic response was reached in both groups. TRG differences were then related to differences in overall survival (*P* = 0.036) and disease-free survival (*P* = 0.020). Median survival was 67 months in the major histologic response group and 44 months in the partial histologic response and no histologic response groups. Disease-free survival at 5 years was 34%, 20%, and 9% respectively. From the data obtained, the role of TRG is identified as an essential pathologic parameter to define the outcomes of patients with colorectal liver metastases, because it correlates with statistically significant overall and disease-free survival of patients in this setting. Liver surgery is usually feasible after administration of anti- VEGF-containing combination regimens. Complications, such as delayed wound healing, gastrointestinal perforation, or bleeding, have been reported when bevacizumab is administered, and could potentially interfere with surgery.[@b13-ott-5-199],[@b15-ott-5-199],[@b55-ott-5-199] However, a recent report has shown that liver surgery can be safely carried out without a significant increase in postoperative complications when bevacizumab is discontinued 6--8 weeks before surgery, although 4--5 weeks may be sufficient.[@b55-ott-5-199] Therefore, bevacizumab in the neoadjuvant setting for treatment of liver metastasis is well tolerated, safe, and effective.

Maintenance therapy with bevacizumab
====================================

The current standard treatment for patients with advanced CRC is administration of all available drugs either sequentially or in combination until disease progression or unacceptable toxicity.[@b58-ott-5-199] Data on the use of bevacizumab as maintenance treatment are provided in [Table 4](#t4-ott-5-199){ref-type="table"}. Management of patients with metastatic CRC with disease progression on a bevacizumab-containing regimen is challenging for the oncologist. The observational BRiTE (Bevacizumab Regimens: Investigation of Treatment Effects) cohort study showed that changing the chemotherapy regimen (but continuing bevacizumab) after disease progression was associated with significantly greater overall survival than continuing chemotherapy without bevacizumab (31.8 months versus 19.9 months; HR 0.48, *P* \< 0.001).[@b59-ott-5-199]

A study enrolling 820 patients with unresectable metastatic CRC who progressed within 3 months after discontinuation of first-line bevacizumab combined with chemotherapy were randomized to second-line fluoropyrimidine-based chemotherapy ± weekly bevacizumab.[@b60-ott-5-199] The choice of either L-OHP-based or CPT-11-based second-line chemotherapy was related to the first-line regimen used. The primary endpoint was overall survival, while secondary endpoints included progression-free survival, response rate, and safety. Median overall survival was 11.2 months for bevacizumab + chemotherapy and 9.8 months for chemotherapy alone (HR 0.81; 95% CI 0.69--0.94; *P* = 0.0062). Median progression-free survival was 5.7 months for bevacizumab + chemotherapy and 4.1 months for chemotherapy alone (HR 0.68; 95% CI 0.59--0.78; *P* \< 0.0001). The response rate was 5.4% for bevacizumab + chemotherapy and 3.9% for chemotherapy alone (*P* = 0.3113). Bevacizumab-related adverse events were not increased when continuing bevacizumab beyond progression. Subsequent subanalysis conducted on the same population assessed the benefit of continuing bevacizumab after progression in relation to *KRAS* status, and the results were that patients with wild-type and mutated *KRAS* tumors were likely to benefit from bevacizumab treatment[@b61-ott-5-199] ([Table 5](#t5-ott-5-199){ref-type="table"}).

Maintenance treatment with fluoropyrimidine and bevacizumab was evaluated in CONcePT (the Combined Oxaliplatin Neuropathy Prevention Trial).[@b62-ott-5-199] This study was designed to monitor patients with metastatic CRC receiving oxaliplatin + bevacizumab as first-line treatment and to evaluate whether an intermittent L-OHP schedule of FOLFOX + bevacizumab reduces cumulative neurotoxicity. Progression-free survival with continuous administration was 7.3 months compared with 12.0 months with the "stop-and-go" strategy. Maintenance therapy with bevacizumab alone was compared with continuous XELOX + bevacizumab therapy in the MACRO (Spanish Maintenance in Colorectal Cancer) trial.[@b63-ott-5-199] Median progression-free survival was 10.4 months in the continuous (control) arm and 9.7 months in the maintenance (investigational) arm, with a HR of 1.11 (95% CI 0.89--1.37); median overall survival was 22.4 versus 21.7 months (HR 1.04), with no benefit for continuous chemotherapy in combination with bevacizumab versus bevacizumab alone. Finally, in the Phase III GERCOR DREAM trial,[@b64-ott-5-199] 700 patients were randomized, after bevacizumab-based induction chemotherapy with FOLFOX, XELOX, or FOLFIRI, to receive either maintenance therapy with bevacizumab alone or a combination of bevacizumab + erlotinib until progression or unacceptable toxicity. After 31 months of follow-up, median progression-free survival was 4.6 months in the bevacizumab group versus 5.8 months in the bevacizumab + erlotinib group (HR 0.73; 95% CI 0.59--0.91, *P* = 0.005).

Predictive biomarkers for bevacizumab treatment
===============================================

Efficacy of bevacizumab therapy is independent of *KRAS*, *BRAF*, or *p53* status.[@b66-ott-5-199] Mutation in KRAS strongly predicts a lack of response to anti-epidermal growth factor receptor antibodies. Selection of KRAS for these analyses was based upon evidence that KRAS is a negative prognostic factor in patients with metastatic CRC[@b67-ott-5-199],[@b68-ott-5-199] and regulates VEGF and other angiogenic factors.[@b69-ott-5-199],[@b70-ott-5-199] To describe better the clinical benefit of bevacizumab according to *KRAS* mutation status in this patient population, Hurwitz et al[@b71-ott-5-199] conducted additional statistical analyses with data from *KRAS* mutation analyses in 230 patients who were treated with IFL in combination with either bevacizumab or placebo in a randomized Phase III study.[@b13-ott-5-199] In both wild-type *KRAS* and mutated *KRAS* groups, addition of bevacizumab to IFL chemotherapy resulted in a statistically significant longer progression-free survival time, with comparable HR for progression. In the wild-type *KRAS* group, the median progression-free survival was 13.5 months for IFL + bevacizumab versus 7.4 months for IFL + placebo (HR 0.44; 95% CI 0.29--0.67; *P* \< 0.0001). For the mutated *KRAS* group, median progression-free survival was 9.3 months for IFL + bevacizumab versus 5.5 months for IFL + placebo (HR 0.41; 95% CI 0.24--0.70; *P* = 0.0008). In the wild-type *KRAS* group, the median overall survival was 27.7 months for IFL + bevacizumab versus 17.6 months for IFL + placebo (HR 0.58; 95% CI 0.34--0.99; *P* = 0.04). For the mutated *KRAS* group, median overall survival was 19.9 months for IFL + bevacizumab versus 13.6 months for IFL + placebo (HR 0.69; 95% CI 0.37--1.31; *P* = 0.26). These data suggest that *KRAS* status does not predict any clinical benefit from addition of bevacizumab to first-line IFL chemotherapy. The predictive value of *KRAS* and *BRAF* gene mutation status in patients receiving capecitabine with or without bevacizumab has been evaluated in the Phase III AGITG MAX trial.[@b72-ott-5-199] The data showed that progression-free survival (*P* = 0.95) and overall survival (*P* = 0.43) did not differ significantly between patients with wild-type *KRAS* and those with mutated *KRAS*. Similarly, no difference emerged in progression-free survival (*P* = 0.46) or overall survival (*P* = 0.32) based on *BRAF* status. The data are summarized in [Table 5](#t5-ott-5-199){ref-type="table"}.

Bevacizumab and anti-EGFR monoclonal antibodies
===============================================

Inhibition of a single signal transduction pathway is unlikely to provide optimal results and, therefore, a combination of agents appears to be a valid strategy. Some studies have suggested that blocking both VEGF and epidermal growth factor receptor pathways may increase antitumoral activity.[@b75-ott-5-199],[@b76-ott-5-199] The BOND-2 study[@b77-ott-5-199] was a Phase II trial that investigated administration of either cetuximab + bevacizumab + CPT-11 or cetuximab + bevacizumab alone in 43 patients with CPT- 11-refractory CRC. Overall survival was 14.5 months versus 11.4 months, respectively, with a similar toxicity profile. The CAIRO-2 study[@b73-ott-5-199] was a Phase III trial of capecitabine, oxaliplatin + bevacizumab ± cetuximab. There was a significant decrease in progression-free survival in the cetuximab + bevacizumab arm as compared with the bevacizumab alone arm (9.8 versus 10.7 months; *P* = 0.019). Overall survival and response rates did not differ significantly between the two groups ([Table 5](#t5-ott-5-199){ref-type="table"}). The PACCE (Panitumumab Advanced Colorectal Cancer Evaluation) trial[@b74-ott-5-199] was a randomized Phase IIIB study that evaluated the efficacy and safety of bevacizumab and chemotherapy ± panitumumab (completely humanized monoclonal antibody against epidermal growth factor receptor) in patients with untreated metastatic CRC. A total of 823 and 230 patients, respectively, were randomly assigned to the oxaliplatin and CPT-11 cohorts. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients due to worse efficacy in the panitumumab arm. Indeed, addition to panitumumab to bevacizumab decreased both progression-free survival (HR 1.27; 95% CI 1.06--1.52) and overall survival (HR 1.43; 95% CI 1.11--1.83). In addition, *KRAS* analysis showed a worst outcome in the panitumumab arm in both wild-type and mutated groups ([Table 5](#t5-ott-5-199){ref-type="table"}). Combination of anti-epidermal growth factor receptor monoclonal antibody with bevacizumab and oxaliplatin-based or CPT-11-based chemotherapy achieved disappointingly low progression-free survival and overall survival ([Table 6](#t6-ott-5-199){ref-type="table"}) and, consequently, such a combination is not recommended for treatment of metastatic CRC.

Treatment-related toxicity
==========================

Addition of bevacizumab increases the risk of hypertension, proteinuria, bleeding, thromboembolic events, and treatment interruption (HR 1.47; 95% CI 1.19--1.83; *P* = 0.0004),[@b31-ott-5-199] particularly with the oxaliplatin-containing regimen.[@b15-ott-5-199] A meta-analysis of five trials found that grade 3 or 4 adverse events were approximately 10% points higher among patients receiving chemotherapy + bevacizumab than those receiving chemotherapy alone, with a statistically significant difference (OR 1.79; 95% CI 1.52--2.11; *P* = 0.01). The pooled estimate found a significantly higher incidence of grade 3 or 4 hypertension (OR 4.19; 95% CI 2.76--6.36; *P* \< 0.01), grade 3 or 4 thromboembolic/thrombotic events (OR 1.75; 95% CI 1.21--2.53; *P* \< 0.01), grade 3 or 4 bleeding (OR 1.87; 95% CI 1.10--3.12; *P* = 0.02), and gastrointestinal perforation (OR 4.81; 95% CI 1.52--15.3; *P* = 0.00) associated with bevacizumab. No statistically significant difference was noted in the incidence of grade 3 or 4 proteinuria, leucopenia, and diarrhea. Elderly patients seem to be at increased risk of stroke and other arterial events following therapy with bevacizumab. However, although the incidence of thromboembolic events increased with age, the increase was not statistically significant after adjustment for baseline Eastern Cooperative Oncology Group performance score and prior history of thromboembolic events.[@b78-ott-5-199] Moreover, other studies failed to find an increased incidence of adverse events in elderly as compared with young patients.[@b79-ott-5-199],[@b80-ott-5-199] Bevacizumab therapy could increase post-surgical complication rate by blocking neoangiogenesis. However, a study of 186 cases failed to demonstrate liver toxicity or increased postoperative morbidity and mortality.[@b81-ott-5-199] Some studies found that surgical complications are more frequent in patients who underwent surgery within 8 weeks of bevacizumab therapy as compared with those stopping the antibody earlier (65.5% versus 30.4%).[@b82-ott-5-199] Therefore, it is currently recommended to stop bevacizumab at least 6 weeks prior surgery, and to resume it after 28 days, making sure that the wound has healed well.[@b50-ott-5-199],[@b83-ott-5-199] A retrospective analysis[@b84-ott-5-199] of two Phase II studies[@b50-ott-5-199],[@b85-ott-5-199] evaluated the role of bevacizumab therapy on liver parenchyma. One of the two studies enrolled 56 patients undergoing neoadjuvant chemotherapy with XELOX + bevacizumab, while in the second study, 50 patients were treated with neoadjuvant FOLFOX or XELOX. In both studies, patients underwent surgery for hepatic metastasectomy 2--5 weeks following the end of chemotherapy. Dilation of hepatic sinusoids, perisinusoidal f ibrosis, and hepatocellular necrosis were reduced in patients who received bevacizumab versus those treated with chemotherapy alone (42.3% versus 52.2%, *P* \< 0.05). These data would suggest that bevacizumab could reduce typical hepatic toxicities of chemotherapeutic drugs used in the neoadjuvant treatment of liver metastases.

Conclusion
==========

Targeted agents have expanded the available treatment options for patients with metastatic CRC. Some investigations are in progress to determine genetic profiles and predictors of therapeutic success and to identify patients who may benefit from targeted agents. The best combination of these biologic drugs with standard chemotherapy agents, such as oxaliplatin, CPT-11, and fluoropyrimidines, remains to be identified. Addition of bevacizumab to fluoropyrimidine- based chemotherapy improved efficacy as compared with chemotherapy alone in both first-line and second-line treatment trials. In detail, first-line chemotherapy including bevacizumab achieved median overall survival values ranging from 16.1 to 28 months, median progression-free survival values between 8.3 and 12.8 months, and a response rate of 24%--65%. The best combination of bevacizumab with standard chemotherapy regimens (oxaliplatin, CPT-11) remains to be established. In fact, on analyzing these data, it is possible to observe high heterogeneity amongst studies. Bevacizumab-based and CPT-11-based regimens appear to be the most advantageous with regard to overall survival, while for oxaliplatin-based therapies, there is only increased progression-free survival in the XELOX subgroup. Also, there are no randomized Phase III studies comparing FOLFOX + bevacizumab versus FOLFIRI + bevacizumab. The value of continuing bevacizumab after disease progression on bevacizumab-containing regimens is still unclear. Therefore, its use in patients with disease progression is not currently recommended outside clinical trials. Bevacizumab combined with chemotherapy achieved a pathologic complete response rate of 9%--11% and a response rate of 40.7%--80%. The rate of curative intent surgery ranged from 14.3%--100%, and an R0 of 6.52%--92.8% was reported, with a reduced incidence of perioperative complications.

*KRAS* and *BRAF* mutation status does not predict a therapeutic response to bevacizumab, and no predictive biomarkers have been identified. Caution should be exercised when combining bevacizumab with cetuximab or panitumumab until further randomized data becomes available. Finally, some trials have tested bevacizumab as a rescue therapy (third-line or more), but the actual benefit in such a setting deserves further investigation.
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###### 

Response rate, progression-free survival, and overall survival of bevacizumab in first-line treatment of metastatic colorectal cancer

  Author                                                Phase study   Treatment                   Population   Median OS (months)   HR, *P* value   Median PFS (months)   HR, *P* value   RR (%)   OR, *P* value
  ----------------------------------------------------- ------------- --------------------------- ------------ -------------------- --------------- --------------------- --------------- -------- ---------------
  Bevacizumab with fluoropyrimidines plus irinotecan                                                                                                                                               
   Hurwitz et al[@b13-ott-5-199]                        III           IFL-placebo                 411          15.6                                 6.2                                   34.8     
                                                                      IFL-BV                      402          20.3                 0.66,           10.6                  0.54,           44.8     *P* = 0.004
                                                                      5-FU-FA-BV                  110          18.3                 *P* \< 0.001    8.8                   *P* \< 0.001    40       
   Stathopoulos et al[@b32-ott-5-199]                   III           IFL-Placebo                 108          25.0                 *P* = 0.1391    NR                    NR              35.2     NR
                                                                      IFL-BV                      114          22.0                                 NR                                    36.8     
   Fuchs et al[@b33-ott-5-199]                          III           FOLFIRI-BV                  57           28.0                 *P* = 0.007     11.2                  *P* = 0.28      57.9     NR
                                                                      mIFL-BV                     60           19.8                                 8.3                                   53.3     
   Sobrero et al[@b34-ott-5-199]                        IV            FOLFIRI-BV                  209          22.2                 NR              11.1                  NR              53.1     NR
   Kopetz et al[@b35-ott-5-199]                         II            FOLFIRI-BV                  43           31.3                 NR              12.8                  NR              65       NR
  Bevacizumab with fluoropyrimidines plus oxaliplatin                                                                                                                                              
   Saltz et al[@b15-ott-5-199]                          III           XELOX-FOLFOX4-placebo       701          19.9                 0.89,           8.0                   0.83,           49       0.90,
                                                                      XELOX-FOLFOX4-BV            699          21.3                 *P* = 0.0769    9.4                   *P* = 0.0023    47       *P* = 0.31
   Hochster et al[@b37-ott-5-199]                       III           FOLFOX-BV                   71           26.1                 NR              NR                    NR              52       NR
                                                                      bFOL-BV                     70           20.4                                                                       39       
                                                                      CapeOx-BV                   72           24.6                                                                       46       
  Bevacizumab with fluoropyrimidines alone                                                                                                                                                         
   Kabbinavar et al[@b11-ott-5-199]                     II            5-FU-FA                     36           13.8                                 NR                    NR              17       NR
                                                                      5-FU-FA-BV (5 mg/g)         35           21.5                 0.63                                                  40       
                                                                      5-FU-FA-BV (10 mg/kg)       33           16.1                 1.17                                                  24       
                                                                      5-FU-FA-placebo             105          12.9                 0.79,           5.5                   0.50,           15       *P* = 0.0552
   Kabbinavar et al[@b12-ott-5-199]                     II            5-FU-FA-BV                  104          16.6                 *P* = 0.159     9.2                   *P* = 0.0002    26       
   Tebbutt et al[@b38-ott-5-199]                        III           Capecitabine                156          18.9                 0.875,          5.7                   0.63,           30.3     *P* = 0.16
                                                                      Capecitabine-BV             157          18.9                 *P* = 0.314     8.5                   *P* \< 0.001    38.1     *P* = 0.006
                                                                      Capecitabine-BV-mitomycin   158          16.4                 0.942,          8.4                   0.59,           45.9     
                                                                                                                                    *P* = 0.642                           *P* \< 0.001             

**Abbreviations:** OS, overall survival; PFS, progression-free survival; RR, response rate; HR, hazard ratio; OR, odds ratio; IFL, bolus 5-fluorouracil-folinic acid-irinotecan; BV, bevacizumab; 5-FU, 5-fluorouracil; FA, folinic acid; FOLFIRI, infusional 5-fluorouracil-bolus folinic acid-irinotecan; mIFL, modified bolus 5-fluorouracil-irinotecan; FOLFOX4, infusional 5-fluorouracil-bolus folinic acid-oxaliplatin; XELOX, capecitabine-oxaliplatin; bFOL, bolus 5-fluorouracil-oxaliplatin; CapeOx, capecitabine-oxaliplatin; NR, not reported.

###### 

Response rate, progression-free survival, and overall survival of bevacizumab in second-line and later-line treatment of metastatic colorectal cancer

  Author                            Phase study     Treatment line      Treatment                                            Population   Median OS (months)   HR, *P* value   Median PFS (months)   HR, *P* value   RR (%)   OR, *P* value
  --------------------------------- --------------- ------------------- ---------------------------------------------------- ------------ -------------------- --------------- --------------------- --------------- -------- ---------------
  Giantonio et al[@b14-ott-5-199]   III             II                  FOLFOX4                                              291          12.9                 0.75,           7.3                   0.61,           22.7     *P* \< 0.001
                                                                        FOLFOX4-BV                                           289          10.8                 *P* = 0.0011    4.7                   *P* \< 0.0001   8.6      
                                                                        BV                                                   243          10.2                                 2.7                                   3.3      
  Yildiz et al[@b41-ott-5-199]      Retrospective   II                  BV + irinotecan-based therapy                        40           14                   NR              6                     NR              20       NR
  Horita et al[@b42-ott-5-199]      II              II                  FOLFIRI-BV                                           25           21.4                 NR              11.6                  NR              32       NR
  Morikawi et al[@b40-ott-5-199]    Cohort          II                  FOLFIRI-BV                                           115          21.6                 NR              8.3                   NR              25       NR
                                                                        FOLFOX4-BV                                           45           16.5                                 7.8                                   29       
  Bennouna et al[@b44-ott-5-199]    II              II                  BV + irinotecan-based or oxaliplatin-based therapy   53           19.3                 NR              6.5                   NR              32       NR
  Chen et al[@b45-ott-5-199]        II              III                 BV-5-FU-FA                                           100          9.1                  NR              3.7                   NR              4        NR
  Park et al[@b46-ott-5-199]        Retrospective   II or later-line    BV-FOLFIRI or FOLFOX4                                40           14                   NR              6.3                   NR              7.5      NR
  Lievre et al[@b47-ott-5-199]      Retrospective   II or later-line    BV + FOLFIRI or FOLFOX4                              31           18.4                 NR              9.7                   NR              32.2     NR
  Kwon et al[@b49-ott-5-199]        Retrospective   III                 BV-FOLFIRI                                           14           10.9                 NR              3.9                   NR              28.5     NR
  Kang et al[@b48-ott-5-199]        Retrospective   III or later-line   BV-FOLFIRI or FOLFOX4                                42           0.5                  NR              5.3                   NR              9.5      NR

**Abbreviations:** OS, overall survival; PFS, progression-free survival; RR, response rate; HR, hazard ratio; OR, odds ratio; BV, bevacizumab; 5-FU, 5-fluorouracil; FA, folinic acid; FOLFIRI, infusional 5-fluorouracil-bolus folinic acidirinotecan; FOLFOX4, infusional 5-fluorouracil-bolus folinic acid-oxaliplatin; NR, not reported.

###### 

Response and resectability of liver metastatic disease treated with neoadjuvant bevacizumab + chemotherapy

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                              Phase Study     Liver metastases   Treatment           Population   RR (%)   Surgery R0 (%)   Curative intent rate (%)
  ----------------------------------- --------------- ------------------ ------------------- ------------ -------- ---------------- --------------------------
  Van Cutsem et al[@b50-ott-5-199]    IV              No operable        BV-FOLFIRI          704          NR       11.7             14.3

                                                                         BV-FOLFOX                        NR       15.4             20.3

  Gruenberger et al[@b16-ott-5-199]   II              Operable           BV-XELOX            56           73.2     92.85            92.85

  Bouganim et al[@b51-ott-5-199]      Retrospective   Operable           BV-oxaliplatin\     60           80       NR               100
                                                                         BV-irinotecan                                              

  Blazer et al[@b52-ott-5-199]        Retrospective   No operable        BV-FOLFIRI-XELIRI   305          40.7     89.83            8.85

                                                                         BV-FOLFOX-XELOX                  62.9     NR               

  Masi et al[@b53-ott-5-199]          II              No operable        BV-FOLFOXIRI        30           NR       43               NR

  Wong et al[@b54-ott-5-199]          II              No operable        BV-CAPOX            45           78       6.52             17.7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** RR, response rate; BV, bevacizumab; FOLFIRI, infusional 5-fluorouracil-bolus folinic acid-irinotecan; FOLFOX, infusional 5-fluorouracil-bolus folinic acidoxaliplatin; XELOX, capecitabine-oxaliplatin; CAPOX, capecitabine-oxaliplatin; NR, not reported.

###### 

Overall survival, progression-free survival, and response rate of bevacizumab continued beyond first progression and in maintenance treatment

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                                       Phase study   Treatment                               Overall   Median OS (months)   HR, *P* value   Median PFS (months)   HR, *P* value   RR (%)   OR, *P* value
  ---------------------------------------------------------------------------- ------------- --------------------------------------- --------- -------------------- --------------- --------------------- --------------- -------- ---------------
  Grothey et al[@b59-ott-5-199],[\*](#tfn5-ott-5-199){ref-type="table-fn"}     Prospective   Post progression treatment without BV   531       19.9                 0.49,           NR                    NR              NR       NR

                                                                                             Post progression treatment with BV      642       31.8                 *P* \< 0.001    NR                                    NR       

  Andre et al[@b60-ott-5-199],[\*](#tfn5-ott-5-199){ref-type="table-fn"}       III           II line CT until PD                     411       9.8                  0.81,           4.1                   0.68,           3.9      *P* = 3113

                                                                                             II line CT + BV until PD                409       11.2                 *P* = 0.0062    5.7                   *P* \< 0.0001   5.4      

  Grothey et al[@b62-ott-5-199],[§](#tfn6-ott-5-199){ref-type="table-fn"}      III           Conventional L-OHP                      139       NR                   NR              7.3                   NR              NR       NR

                                                                                             Intermittent L-OHP + BV                           NR                                   12                                    NR       

  Diaz-Rubio et al[@b63-ott-5-199],[§](#tfn6-ott-5-199){ref-type="table-fn"}                 III XELOX + BV →                        239       23.3                 1.05,           10.4                  1.10,           47%      0.95

                                                                                             XELOX + BV\                             241       20.0                 *P* = 0.65      9.7                   *P* = 0.38      49%      
                                                                                             XELOX + BV → BV                                                                                                                       

  Tournigand et al[@b64-ott-5-199],[§](#tfn6-ott-5-199){ref-type="table-fn"}   III           BV + erlotinib                          222       NR                   NR              5.76                  0.73,           NR       NR

                                                                                             BV                                      226       NR                                   4.67                  *P* = 0.0050    NR       

  Johnsonn et al[@b65-ott-5-199],[§](#tfn6-ott-5-199){ref-type="table-fn"}     III           BV + erlotinib                          249       NR                   NR              5.9                   0.81,           NR       NR

                                                                                             BV                                                NR                                   4.2                   *P* = 0.24      NR       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

BV continued beyond first progression;

BV used as maintenance treatment.

**Abbreviations:** OR, odds ratio; OS, overall survival; PFS, progression-free survival; BV, bevacizumab; CT, chemotherapy; HR, hazard ratio; L-OHP, oxaliplatin; XELOX, capecitabine-oxaliplatin; NR, not reported; PD, progression disease; RR, response rate.

###### 

Response rate, overall survival, and progression-free survival: comparability of results between wild-type *KRAS* versus mutated *KRAS* groups and wild-type *BRAF* versus mutated *BRAF* groups

  Author                             Treatment                  Population   RR (%)   OR, *P* value   Median OS (months)   HR, *P* value     Median PFS (months)   HR, *P* value
  ---------------------------------- -------------------------- ------------ -------- --------------- -------------------- ----------------- --------------------- ----------------
  Hurwitz et al[@b71-ott-5-199]      IFL-placebo wt-Kras        67           37.3     *P* = 0.006     17.6                 0.58,             7.4                   0.44,
                                     IFL-BV wt-Kras             85           60       *P* = 0.86      27.7                 *P* = 0.04;       13.5                  *P* \< 0.0001;
                                     IFL-placebo mut-Kras       34           41.2                     13.6                 0.69,             5.5                   0.41,
                                     IFL-BV mut-Kras            44           44                       19.9                 *P* = 0.26        9.3                   *P* = 0.0008
  Price et al[@b72-ott-5-199]        Cape wt-Kras               315          27.1     *P* = 0.02      20                   NR                5.9                   NR
                                     Cape mut-Kras                           48.5                     22.8                                   6.2                   
                                     CB wt-Kras                              41                       19.8                 NR                8.8                   NR
                                     CB mut-Kras                             24.2                     17.6                                   8.2                   
                                     CBM wt-Kras                             44.7                     21.4                 NR                6                     NR
                                     CBM mut-Kras                            45.8                     6.3                                    2.5                   
                                     Cape wt-Braf               315          35.5     *P* = 0.91      20.8                 NR                9.1                   NR
                                     Cape mut-Braf                           25                       9.2                                    5.5                   
                                     CB wt-Braf                              35.6                                                                                  
                                     CB mut-Braf                             42.9                                                                                  
                                     CBM wt-Braf                             48.2                                                                                  
                                     CBM mut-Braf                            27.8                                                                                  
  Tol et al[@b73-ott-5-199]          Cape-L-OHP-BVwt-Kras       156          50       *P* = 0.16      22.4                 *P* = 0.82        10.6                  *P* = 0.80
                                     Cape-L-OHP-BV mut-Kras     108          59.2     *P* = 0.03      24.9                 *P* = 0.06        12.5                  *P* = 0.04
                                     Cape-L-OHP-BV-C wt-Kras    158          61.4                     21.8                                   10.5                  
                                     Cape-L-OHP-BV-C mut-Kras   98           45.9                     17.2                                   8.1                   
  Hecht et al[@b74-ott-5-199]        L-OHP-CT-BV wt-Kras        203          56       NR              24.5                 HR, 1.89;         11.5                  HR, 1.36;
                                     L-OHP-CT-BV-P wt-Kras      201          50                       20.7                                   9.8                   
                                     L-OHP-CT-BV mut-Kras       125          44       NR              19.3                 HR, 1.02          11                    HR, 1.25
                                     L-OHP-CT-BV-P mut-Kras     135          47                       19.3                                   10.4                  
                                     CPT-11-CT-BV wt-Kras       58           48       NR              19.8                 HR, 1.28 to NR;   12.5                  HR, 1.50;
                                     CPT-11-CT-BV-P wt-Kras     57           54                       NR                   HR, 2.14          10                    
                                     CPT-11-CT-BV mut-Kras      39           38       NR              20.5                                   11.9                  HR, 1.19
                                     CPT-11-CT-BV-P mut-Kras    47           30                       17.8                                   8.3                   
  Van Cutsem et al[@b61-ott-5-199]   II line CT wt-Kras         316          NR       NR              11.1                 HR, 0.69          4.5                   HR, 0.61
                                     II line CT + BV wt-Kras    300          NR                       15.4                 *P* = 0.0052;     6.4                   *P* \< 0.0001;
                                     II line CT mut-Kras                     NR       NR              10                   HR, 0.91          4.1                   HR, 0.70
                                     II line CT + BV mut-Kras                NR                       10.4                 *P* = 0.4969      5.5                   *P* = 0.0027

**Note:** All studies are Phase III.

**Abbreviations:** OS, overall survival; PFS, progression-free survival; RR, response rate; HR, hazard ratio; OR, odds ratio; IFL, bolus 5-fluorouracil-folinic acid-irinotecan; BV, bevacizumab; Cape, capecitabine; CB, capecitabine, bevacizumab; CBM, capecitabine, bevacizumab, mitomycin; wt, wild-type; mut, mutated; vs, versus; L-OHP, oxaliplatin; C, cetuximab; CPT-11, irinotecan; L-OHP-CT, oxaliplatin-based chemotherapy; CPT-11-CT, irinotecan-based chemotherapy; P, panitumumab; NR, not reported.

###### 

Bevacizumab and anti-epithelial growth factor receptor monoclonal antibodies

  Author                        Phase study   Treatment            Population   Median OS (months)   HR, *P* value   Median PFS (months)   HR, *P* value   RR (%)   OR, *P* value
  ----------------------------- ------------- -------------------- ------------ -------------------- --------------- --------------------- --------------- -------- ---------------
  Saltz et al[@b77-ott-5-199]   II            CPT-11-BV-Cmab       43           14.5                 NR              7.3                   NR              37       NR
                                              BV-Cmab              40           11.4                                 4.9                                   20       
  Tol et al[@b73-ott-5-199]     III           Cape-L-OHP-BV        368          20.3                 *P* = 0.16      10.7                  *P* = 0.01      50       *P* = 0.49
                                              Cape-L-OHP-BC-Cmab   368          19.4                                 9.4                                   52.7     
  Hecht et al[@b74-ott-5-199]   IIIB          L-OHP-CT-BV          410          24.5                 HR, 1.43        11.4                  HR, 1.06        48       NR
                                              L-OHP-CT-BV-Pmab     413          19.4                                 10                                    46       
                                              CPT-11-CT-BV         115          20.5                 HR, 1.42        11.7                  HR, 1.19        46       NR
                                              CPT-11-CT-BV-Pmab    115          20.7                                 10.1                                  49       

**Abbreviations:** OS, overall survival; PFS, progression-free survival; RR, response rate; HR, hazard ratio; OR, odds ratio; BV, bevacizumab; Cmab, catuximab; Pmab, panitumumab; Cape, capecitabine; L-OHP, oxaliplatin; CPT-11, irinotecan; L-OHP-CT, oxaliplatin-based chemotherapy; CPT-11-CT, CPT-11-based chemotherapy; NR, not reported.
